Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+breast cancer cells

被引:9
|
作者
Murad, Rabi [1 ]
Avanes, Arabo [2 ]
Ma, Xinyi [1 ]
Geng, Shuhui [2 ]
Mortazavi, Ali [1 ]
Momand, Jamil [2 ]
机构
[1] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92617 USA
[2] Calif State Univ Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90032 USA
基金
美国国家卫生研究院;
关键词
breast cancer; Herceptin; trastuzumab; drug resistance; FoxJ3; Sox2; ATAC-seq; differentially expressed genes; METASTATIC BREAST-CANCER; T-DARPP; EXPRESSION; RECEPTOR; CHEMOTHERAPY; WOMEN; LINES; SEQ;
D O I
10.1016/j.gene.2021.145808
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We set out to uncover transcriptome and chromatin landscape changes that occur in HER2 + breast cancer (BC) cells upon acquiring resistance to trastuzumab. RNA-seq analysis was applied to two independently-derived BC cell lines with acquired resistance to trastuzumab (SKBr3.HerR and BT-474HerR) and their parental drugsensitive cell lines (SKBr3 and BT-474). Chromatin landscape analysis indicated that the most significant increase in accessibility in resistant cells occurs in PPP1R1B within a segment spanning introns 1b through intron 3. Footprint analysis of this segment revealed that FoxJ3 (within intron 2) and Pou5A1/Sox2 (within inton 3) transcription factor motifs are protected in resistant cells. Overall, 344 shared genes were upregulated in both resistant cell lines relative to their parental counterparts and 453 shared genes were downregulated in both resistant cell lines relative to their parental counterparts. In resistant cells, genes associated with autophagy and mitochondria organization are upregulated and genes associated with ribosome assembly and cell cycle are downregulated relative to parental cells. The five top upregulated genes in drug-resistant breast cancer cells are APOD, AZGP1, ETV5, ALPP, and PPP1R1B. This is the first report of increased chromatin accessibility within PPP1R1B associated with its t-Darpp transcript increase, and points to a possible mechanism for its activation in trastuzumab-resistant cells.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+breast cancer
    Iwata, H.
    Yamamoto, N.
    Masuda, N.
    Bando, H.
    Kuroi, K.
    Ohno, S.
    Kasai, H.
    Morita, S.
    Sakurai, T.
    Toi, M.
    BREAST, 2015, 24 : S95 - S95
  • [32] The trastuzumab era: current and upcoming targeted HER2+breast cancer therapies
    Kreutzfeldt, Jordyn
    Rozeboom, Brett
    Dey, Nandini
    De, Pradip
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (04): : 1045 - 1067
  • [33] A gene expression signature that predicts for trastuzumab response in HER2+breast cancer
    Abukhdeir, Abde M.
    Najor, Matthew S.
    Turturro, Sanja B.
    Armstrong, Andrew R.
    McDonald, Andrew
    Fogg, Lou
    Cobleigh, Melody A.
    CANCER RESEARCH, 2018, 78 (04)
  • [34] miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+Breast Cancer
    Cabello, Paula
    Torres-Ruiz, Sandra
    Adam-Artigues, Anna
    Fores-Martos, Jaume
    Martinez, Maria Teresa
    Hernando, Cristina
    Zazo, Sandra
    Madoz-Gurpide, Juan
    Rovira, Ana
    Burgues, Octavio
    Rojo, Federico
    Albanell, Joan
    Lluch, Ana
    Bermejo, Begona
    Cejalvo, Juan Miguel
    Eroles, Pilar
    CANCERS, 2023, 15 (07)
  • [35] TGFBI promoter methylation validation as an epigenetic biomarker for trastuzumab resistance in HER2+breast cancer patients cohort
    Pla, H.
    Diaz-Lagares, A.
    Hernandez, A.
    Oliveras, G.
    Perez-Bueno, F.
    Esteller, M.
    Puig, T.
    Palomeras, S.
    Vinas, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S38 - S38
  • [36] Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer
    Merry, Callie R.
    McMahon, Sarah
    Forrest, Megan E.
    Bartels, Cynthia F.
    Saiakhova, Alina
    Bartel, Courtney A.
    Scacheri, Peter C.
    Thompson, Cheryl L.
    Jackson, Mark W.
    Harris, Lyndsay N.
    Khalil, Ahmad M.
    ONCOTARGET, 2016, 7 (33) : 53230 - 53244
  • [37] Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
    Ami Hori
    Masafumi Shimoda
    Yasuto Naoi
    Naofumi Kagara
    Tomonori Tanei
    Tomohiro Miyake
    Kenzo Shimazu
    Seung Jin Kim
    Shinzaburo Noguchi
    Breast Cancer Research, 21
  • [38] HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch
    Dubianski, R.
    Sarnowska, E.
    Leszczynski, M.
    Kubala, S.
    Olszewski, W.
    Rusetska, N.
    Jagiello-Gruszfeld, A. I.
    Konopinski, R.
    Sarnowski, T. J.
    Siedlecki, J. A.
    Nowecki, Z. I.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
    Hori, Ami
    Shimoda, Masafumi
    Naoi, Yasuto
    Kagara, Naofumi
    Tanei, Tomonori
    Miyake, Tomohiro
    Shimazu, Kenzo
    Kim, Seung Jin
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [40] Targeting trastuzumab-resistant HER2+breast cancer with a HER3-targeting nanoparticle
    Sims, Jessica
    Taguaim, Michael
    Hanson, Chris
    Cui, Xiaojiang
    Medina-Kauwe, Lali K.
    CANCER RESEARCH, 2014, 74 (19)